<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Treace Medical Concepts Inc — News on 6ix</title>
<link>https://6ix.com/company/treace-medical-concepts-inc</link>
<description>Latest news and press releases for Treace Medical Concepts Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 24 Apr 2026 11:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/treace-medical-concepts-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835cb2678dffbe2df11d092.webp</url>
<title>Treace Medical Concepts Inc</title>
<link>https://6ix.com/company/treace-medical-concepts-inc</link>
</image>
<item>
<title>Treace to Report First Quarter 2026 Financial Results on May 8, 2026</title>
<link>https://6ix.com/company/treace-medical-concepts-inc/news/treace-to-report-first-quarter-2026-financial-results-on-may-8-2026</link>
<guid isPermaLink="true">https://6ix.com/company/treace-medical-concepts-inc/news/treace-to-report-first-quarter-2026-financial-results-on-may-8-2026</guid>
<pubDate>Fri, 24 Apr 2026 11:05:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., April 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the first quarter 2026 before the start of trading on Friday, May 8, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET. Investor</description>
</item>
<item>
<title>Treace Announces First Surgical Cases with the SuperBite™ Compression Screw System</title>
<link>https://6ix.com/company/treace-medical-concepts-inc/news/treace-announces-first-surgical-cases-with-the-superbitetm-compression-screw-system</link>
<guid isPermaLink="true">https://6ix.com/company/treace-medical-concepts-inc/news/treace-announces-first-surgical-cases-with-the-superbitetm-compression-screw-system</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>New portfolio addition taps into incremental procedures throughout the foot and ankle; strengthens Treace’s comprehensive suite of technologies for its</description>
</item>
<item>
<title>Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results</title>
<link>https://6ix.com/company/treace-medical-concepts-inc/news/treace-medical-concepts-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/treace-medical-concepts-inc/news/treace-medical-concepts-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Fri, 27 Feb 2026 12:05:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the fourth quarter and full-year ended December 31, 2025. Recent Highlights Generated revenue of $62.5 million in fourth quarter 2025 and revenue of $212.7 million for the full-year 2025, an increase of 2% c</description>
</item>
<item>
<title>Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2026 ACFAS Annual Scientific Conference</title>
<link>https://6ix.com/company/treace-medical-concepts-inc/news/treace-highlights-new-product-innovations-and-updated-positive-clinical-study-data-at-the-2026-acfas-annual-scientific-conference</link>
<guid isPermaLink="true">https://6ix.com/company/treace-medical-concepts-inc/news/treace-highlights-new-product-innovations-and-updated-positive-clinical-study-data-at-the-2026-acfas-annual-scientific-conference</guid>
<pubDate>Tue, 24 Feb 2026 12:05:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™, MTA3D™, and SpeedMTP® clinical studies at the American College of Foot and Ankle Surgeons (“ACFAS”) Annual Scientific Conference in Las Veg</description>
</item>
<item>
<title>Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026</title>
<link>https://6ix.com/company/treace-medical-concepts-inc/news/treace-updates-date-fourth-quarter-221300722</link>
<guid isPermaLink="true">https://6ix.com/company/treace-medical-concepts-inc/news/treace-updates-date-fourth-quarter-221300722</guid>
<pubDate>Thu, 12 Feb 2026 22:13:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the fourth quarter and full year of 2025 before the open of trading on Friday, February 27, 2026. Company management will host a conference call to discuss financial results beginning a</description>
</item>
<item>
<title>Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue</title>
<link>https://6ix.com/company/treace-medical-concepts-inc/news/treace-announces-preliminary-unaudited-fourth-120500470</link>
<guid isPermaLink="true">https://6ix.com/company/treace-medical-concepts-inc/news/treace-announces-preliminary-unaudited-fourth-120500470</guid>
<pubDate>Tue, 13 Jan 2026 12:05:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced its preliminary, unaudited fourth quarter and full-year 2025 revenue results. Highlights: Preliminary revenue of $62.1 million to $62.5 million in the fourth quarter of 2025, an approximate 9% decrease at the midpoint over the s</description>
</item>
<item>
<title>Treace Announces First Surgical Case Utilizing Lapiplasty® Lightning™ Technology</title>
<link>https://6ix.com/company/treace-medical-concepts-inc/news/treace-announces-first-surgical-case-210500646</link>
<guid isPermaLink="true">https://6ix.com/company/treace-medical-concepts-inc/news/treace-announces-first-surgical-case-210500646</guid>
<pubDate>Thu, 08 Jan 2026 21:05:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced the successful completion of the first case utilizing its Lapiplasty® Lightning™ technology. Lightning technology expands upon Treace’s market-leading Lapiplasty® System with advanced new instrumentation designed to reduce surgi</description>
</item>
<item>
<title>Treace to Present at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/treace-medical-concepts-inc/news/treace-present-44th-annual-j-210500246</link>
<guid isPermaLink="true">https://6ix.com/company/treace-medical-concepts-inc/news/treace-present-44th-annual-j-210500246</guid>
<pubDate>Tue, 30 Dec 2025 21:05:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that John T. Treace, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, beginning at approximately 7:30 am PT. A live webcast and replay of the fireside cha</description>
</item>
<item>
<title>Treace Medical Secures Up to $175 Million in Debt Financing</title>
<link>https://6ix.com/company/treace-medical-concepts-inc/news/treace-medical-secures-175-million-133000029</link>
<guid isPermaLink="true">https://6ix.com/company/treace-medical-concepts-inc/news/treace-medical-secures-175-million-133000029</guid>
<pubDate>Thu, 18 Dec 2025 13:30:00 GMT</pubDate>
<description>New 5-Year Agreement Provides Continued Financial Strength & FlexibilityPONTE VEDRA, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it has entered into a new five year $175 million senior secured loan arrangement with credit funds managed by SLR Capital Partners, consisting of $60 millio</description>
</item>
<item>
<title>Treace Announces Participation in Two Upcoming Investor Conferences</title>
<link>https://6ix.com/company/treace-medical-concepts-inc/news/treace-announces-participation-two-upcoming-130500130</link>
<guid isPermaLink="true">https://6ix.com/company/treace-medical-concepts-inc/news/treace-announces-participation-two-upcoming-130500130</guid>
<pubDate>Fri, 07 Nov 2025 13:05:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will participate in the following upcoming investor conferences. The UBS Global Healthcare Conference on Monday, November 10, 2025, with a fireside chat at 11:45 am ET; andThe Stifel 2025 Healthcare Conference on Tuesday, Nov</description>
</item>
<item>
<title>Treace Medical Concepts Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/treace-medical-concepts-inc/news/treace-medical-concepts-reports-third-210500801</link>
<guid isPermaLink="true">https://6ix.com/company/treace-medical-concepts-inc/news/treace-medical-concepts-reports-third-210500801</guid>
<pubDate>Thu, 06 Nov 2025 21:05:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the third quarter ended September 30, 2025. Recent Highlights Generated revenue of $50.2 million in third quarter 2025 representing growth of 11% over the same period in 2024. Reported third quarter 2025 net</description>
</item>
<item>
<title>Treace to Report Third Quarter 2025 Financial Results on November 6, 2025</title>
<link>https://6ix.com/company/treace-medical-concepts-inc/news/treace-report-third-quarter-2025-200500717</link>
<guid isPermaLink="true">https://6ix.com/company/treace-medical-concepts-inc/news/treace-report-third-quarter-2025-200500717</guid>
<pubDate>Thu, 23 Oct 2025 20:05:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the third quarter 2025 after the close of trading on Thursday, November 6, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Inv</description>
</item>
<item>
<title>Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2025 American Orthopaedic Foot & Ankle Society Annual Meeting</title>
<link>https://6ix.com/company/treace-medical-concepts-inc/news/treace-highlights-product-innovations-updated-110500331</link>
<guid isPermaLink="true">https://6ix.com/company/treace-medical-concepts-inc/news/treace-highlights-product-innovations-updated-110500331</guid>
<pubDate>Wed, 10 Sep 2025 11:05:00 GMT</pubDate>
<description>PONTE VERDE, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™ and MTA3D™ clinical studies at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting 2025 in Savannah, Georgia from Septembe</description>
</item>
<item>
<title>Treace Medical Concepts Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/treace-medical-concepts-inc/news/treace-medical-concepts-reports-second-200500747</link>
<guid isPermaLink="true">https://6ix.com/company/treace-medical-concepts-inc/news/treace-medical-concepts-reports-second-200500747</guid>
<pubDate>Thu, 07 Aug 2025 20:05:00 GMT</pubDate>
<description>Announces Full Market Release of Three New Bunion TechnologiesPONTE VEDRA, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights Generated revenue of $47.4 million in second quarter 2025 representing growth of 7% ove</description>
</item>
<item>
<title>Treace Medical to Host Investor Day Highlighting New Products on September 3, 2025</title>
<link>https://6ix.com/company/treace-medical-concepts-inc/news/treace-medical-host-investor-day-200100371</link>
<guid isPermaLink="true">https://6ix.com/company/treace-medical-concepts-inc/news/treace-medical-host-investor-day-200100371</guid>
<pubDate>Thu, 07 Aug 2025 20:01:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced plans to host an investor day at 9:00 am E.T. on September 3, 2025, in New York, New York. The event will include presentations by members of management and experienced surgeon users, highlighting their experiences with the expa</description>
</item>
<item>
<title>Treace Announces Peer-Reviewed Publication of Four-Year Results of the ALIGN3D™ Lapiplasty® Multicenter Prospective Clinical Study</title>
<link>https://6ix.com/company/treace-medical-concepts-inc/news/treace-announces-peer-reviewed-publication-200500940</link>
<guid isPermaLink="true">https://6ix.com/company/treace-medical-concepts-inc/news/treace-announces-peer-reviewed-publication-200500940</guid>
<pubDate>Tue, 05 Aug 2025 20:05:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced the peer-reviewed publication of the four-year interim results from its ALIGN3D™ multicenter prospective study demonstrating positive clinical and radiographic outcomes of the Lapiplasty® Procedure in the Journal of Foot & Ankle</description>
</item>
<item>
<title>Treace to Report Second Quarter 2025 Financial Results on August 7, 2025</title>
<link>https://6ix.com/company/treace-medical-concepts-inc/news/treace-report-second-quarter-2025-200500785</link>
<guid isPermaLink="true">https://6ix.com/company/treace-medical-concepts-inc/news/treace-report-second-quarter-2025-200500785</guid>
<pubDate>Thu, 24 Jul 2025 20:05:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the second quarter 2025 after the close of trading on Thursday, August 7, 2025. Company management will host a conference</description>
</item>
<item>
<title>Treace Files Patent Infringement Suit Against Zimmer Biomet to Protect Lapiplasty® Bunion Technology</title>
<link>https://6ix.com/company/treace-medical-concepts-inc/news/treace-files-patent-infringement-suit-170000882</link>
<guid isPermaLink="true">https://6ix.com/company/treace-medical-concepts-inc/news/treace-files-patent-infringement-suit-170000882</guid>
<pubDate>Thu, 05 Jun 2025 17:00:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., June 05, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® procedures, today announced that it filed a lawsuit against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. (collectively, “Zimmer”) (NYSE: ZBH), alleging infringement of 4 patents related to</description>
</item>
<item>
<title>Treace Medical Concepts Reports First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/treace-medical-concepts-inc/news/treace-medical-concepts-reports-first-200500609</link>
<guid isPermaLink="true">https://6ix.com/company/treace-medical-concepts-inc/news/treace-medical-concepts-reports-first-200500609</guid>
<pubDate>Thu, 08 May 2025 20:05:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Generated revenue of $52.6 million in first quarter 2025 representing growth of 3% over</description>
</item>
<item>
<title>Treace to Report First Quarter 2025 Financial Results on May 8, 2025</title>
<link>https://6ix.com/company/treace-medical-concepts-inc/news/treace-report-first-quarter-2025-200500343</link>
<guid isPermaLink="true">https://6ix.com/company/treace-medical-concepts-inc/news/treace-report-first-quarter-2025-200500343</guid>
<pubDate>Thu, 24 Apr 2025 20:05:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the first quarter 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference cal</description>
</item>
</channel>
</rss>